Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Claxton

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Pharmacoeconomics|June 18, 2005
Incorporation of uncertainty in health economic modelling studiesAnthony O'Hagan, Christopher McCabe, Ron Akehurst, et al.
Health Economics|July 5, 2016
Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology AppraisalAlec Morton, Amanda I Adler, David Bell, et al.
BMJ (Clinical Research Ed.)|September 29, 2016
Cancer Drugs Fund requires further reformRichard Grieve, Keith Abrams, Karl Claxton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to ThoughtThomas Wilkinson, Mark J Sculpher, Karl Claxton, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 29, 2012
Methods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcersMarta O Soares, Jo C Dumville, Rebecca L Ashby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value FrameworkDaniel C Malone, Nancy S Berg, Karl Claxton, et al.
Schizophrenia Research|September 18, 2004
The heterogeneity of schizophrenia in disease statesPenny E Mohr, C Michael Cheng, Karl Claxton, et al.
Gates Open Research|February 12, 2021
What next after GDP-based cost-effectiveness thresholds?Y-Ling Chi, Mark Blecher, Kalipso Chalkidou, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Pharmacoeconomics|June 18, 2005
Incorporation of uncertainty in health economic modelling studiesAnthony O'Hagan, Christopher McCabe, Ron Akehurst, et al.
Health Economics|July 5, 2016
Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology AppraisalAlec Morton, Amanda I Adler, David Bell, et al.
BMJ (Clinical Research Ed.)|September 29, 2016
Cancer Drugs Fund requires further reformRichard Grieve, Keith Abrams, Karl Claxton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 19, 2016
The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to ThoughtThomas Wilkinson, Mark J Sculpher, Karl Claxton, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 29, 2012
Methods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcersMarta O Soares, Jo C Dumville, Rebecca L Ashby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value FrameworkDaniel C Malone, Nancy S Berg, Karl Claxton, et al.
Schizophrenia Research|September 18, 2004
The heterogeneity of schizophrenia in disease statesPenny E Mohr, C Michael Cheng, Karl Claxton, et al.
Gates Open Research|February 12, 2021
What next after GDP-based cost-effectiveness thresholds?Y-Ling Chi, Mark Blecher, Kalipso Chalkidou, et al.
Pageof 12